• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发展中国家的慢性气流受限:负担与优先事项

Chronic airflow limitation in developing countries: burden and priorities.

作者信息

Aït-Khaled Nadia, Enarson Donald A, Ottmani Salah, El Sony Asma, Eltigani Mai, Sepulveda Ricardo

机构信息

International Union Against Tuberculosis and Lung Diseases, Paris, France.

出版信息

Int J Chron Obstruct Pulmon Dis. 2007;2(2):141-50.

PMID:18044686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2695613/
Abstract

Respiratory disease has never received priority in relation to its impact on health. Estimated DALYs lost in 2002 were 12% globally (similar for industrialized and developing countries). Chronic airflow limitation (due mainly to asthma and COPD) alone affects more than 100 million persons in the world and the majority of them live in developing countries. International guidelines for management of asthma (GINA) and COPD (GOLD) have been adopted and their cost-effectiveness demonstrated in industrialized countries. As resources are scarce in developing countries, adaptation of these guidelines using only essential drugs is required. It remains for governments to set priorities. To make these choices, a set of criteria have been proposed. It is vital that the results of scientific investigations are presented in these terms to facilitate their use by decision-makers. To respond to this emerging public health problem in developing countries, WHO has developed 2 initiatives: "Practical Approach to Lung Health (PAL)" and the Global Alliance Against Chronic Respiratory Diseases (GARD)", and the International Union Against Tuberculosis and Lung Diseases (The Union) has launched a new initiative to increase affordability of essential asthma drugs for patients in developing countries termed the "Asthma Drug Facility" (ADF), which could facilitate the care of patients living in these parts of the world.

摘要

呼吸系统疾病对健康的影响从未得到过应有的重视。2002年全球估计损失的伤残调整生命年(DALYs)为12%(工业化国家和发展中国家情况相似)。仅慢性气流受限(主要由哮喘和慢性阻塞性肺疾病导致)就影响着全球超过1亿人,其中大多数生活在发展中国家。哮喘管理国际指南(GINA)和慢性阻塞性肺疾病管理国际指南(GOLD)已被采用,且在工业化国家证明了其成本效益。由于发展中国家资源稀缺,需要采用仅使用基本药物的方式来调整这些指南。政府仍需确定优先事项。为做出这些选择,已提出了一套标准。至关重要的是,科学调查结果应以这些标准呈现,以便决策者使用。为应对发展中国家这一新兴的公共卫生问题,世界卫生组织制定了两项举措:“肺部健康实用方法(PAL)”和全球抗击慢性呼吸道疾病联盟(GARD),国际防痨和肺部疾病联盟(防痨联盟)发起了一项新倡议,以提高发展中国家患者基本哮喘药物的可及性,该倡议称为“哮喘药物设施”(ADF),这可能有助于为世界这些地区的患者提供护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fe/2695613/ee7ff34c8e2b/copd-2-141f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fe/2695613/455bfe06b3ec/copd-2-141f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fe/2695613/ee7ff34c8e2b/copd-2-141f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fe/2695613/455bfe06b3ec/copd-2-141f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90fe/2695613/ee7ff34c8e2b/copd-2-141f2.jpg

相似文献

1
Chronic airflow limitation in developing countries: burden and priorities.发展中国家的慢性气流受限:负担与优先事项
Int J Chron Obstruct Pulmon Dis. 2007;2(2):141-50.
2
Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries.在发展中国家,获取吸入性糖皮质激素是改善哮喘护理质量的关键。
Allergy. 2007 Mar;62(3):230-6. doi: 10.1111/j.1398-9995.2007.01326.x.
3
The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.以学校为基础的家庭哮喘教育项目对5至18岁确诊哮喘儿童生活质量和哮喘发作次数的有效性:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335.
4
Impact of active and passive smoking as risk factors for asthma and COPD in women presenting to primary care in Syria: first report by the WHO-GARD survey group.主动和被动吸烟对在叙利亚初级保健就诊的女性哮喘和 COPD 的影响:世卫组织全球哮喘和呼吸疾病监测(GARD)调查小组的首次报告。
Int J Chron Obstruct Pulmon Dis. 2013;8:473-82. doi: 10.2147/COPD.S50551. Epub 2013 Oct 2.
5
Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management.发展中国家的慢性呼吸道疾病:负担以及预防与管理策略
Bull World Health Organ. 2001;79(10):971-9. Epub 2001 Nov 1.
6
Practical approach to lung health in Nepal: better prescribing and reduction of cost.尼泊尔肺部健康的实用方法:优化处方与降低成本
Trop Med Int Health. 2006 May;11(5):765-72. doi: 10.1111/j.1365-3156.2006.01599.x.
7
Access to essential medicines to treat chronic respiratory disease in low-income countries.低收入国家获取治疗慢性呼吸道疾病的基本药物的情况。
Int J Tuberc Lung Dis. 2016 Jun;20(6):717-28. doi: 10.5588/ijtld.15.0734.
8
Systems for the management of respiratory disease in primary care--an international series: Pakistan.基层医疗中呼吸系统疾病管理系统——国际系列:巴基斯坦
Prim Care Respir J. 2009 Mar;18(1):3-9. doi: 10.3132/pcrj.2008.00039.
9
GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership.全球哮喘防治创议(GARD),一种与慢性呼吸道疾病作斗争的新方法,从以疾病为导向的项目到全球伙伴关系。
J Thorac Dis. 2017 Nov;9(11):4676-4689. doi: 10.21037/jtd.2017.11.91.
10
[Global alliance against chronic respiratory diseases].全球抗击慢性呼吸道疾病联盟
Pneumonol Alergol Pol. 2008;76(3):160-9.

引用本文的文献

1
Respiratory symptoms, exacerbations and sleep disturbances are more common among participants with asthma and chronic airflow limitation: an epidemiological study in Estonia, Iceland and Sweden.在患有哮喘和慢性气流受限的参与者中,呼吸道症状、病情加重和睡眠障碍更为常见:爱沙尼亚、冰岛和瑞典的一项流行病学研究。
BMJ Open Respir Res. 2024 Feb 19;11(1):e002063. doi: 10.1136/bmjresp-2023-002063.
2
The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis.气流受限与肺鳞癌的关系:来自孟德尔随机化分析的证据。
J Cancer Res Clin Oncol. 2023 Aug;149(10):6999-7006. doi: 10.1007/s00432-023-04612-6. Epub 2023 Feb 28.
3

本文引用的文献

1
Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children.氟替卡松与倍氯米松或布地奈德用于成人和儿童慢性哮喘的比较。
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD002310. doi: 10.1002/14651858.CD002310.pub4.
2
[How to make easier the treatment of asthma].[如何使哮喘治疗更简便]
Rev Mal Respir. 2006 Sep;23(4 Pt 2):10S76-10S79.
3
Health inequities, environmental insecurity and the attainment of the millennium development goals in sub-Saharan Africa: the case study of Zambia.撒哈拉以南非洲地区的健康不平等、环境不安全与千年发展目标的实现:以赞比亚为例
The Prevalence, Clinical Picture, and Triggers of Allergic Rhinitis in Saudi Population: A Systematic Review and Meta-Analysis.
沙特人群中变应性鼻炎的患病率、临床表现及诱发因素:一项系统评价和Meta分析
J Asthma Allergy. 2022 Dec 23;15:1831-1849. doi: 10.2147/JAA.S391142. eCollection 2022.
4
Challenges in the diagnosis of asthma in children, what are the solutions? A scoping review of 3 countries in sub Saharan Africa.儿童哮喘诊断中的挑战,有哪些解决方案?撒哈拉以南非洲 3 国的范围综述。
Respir Res. 2022 Sep 19;23(1):254. doi: 10.1186/s12931-022-02170-y.
5
Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler Device in Greek Patients with Chronic Obstructive Pulmonary Disease and Comorbidities: The AEOLOS Study.在希腊慢性阻塞性肺疾病及合并症患者中,使用埃尔喷吸入器装置递送沙美特罗/氟替卡松固定剂量复方制剂的临床疗效评估:AEOLOS研究
J Pers Med. 2021 Nov 8;11(11):1159. doi: 10.3390/jpm11111159.
6
Severity and prevalence of allergic rhinitis among school children, Jazan Region Saudi Arabia.沙特阿拉伯吉赞地区学童过敏性鼻炎的严重程度和患病率
J Family Med Prim Care. 2019 Feb;8(2):663-668. doi: 10.4103/jfmpc.jfmpc_294_18.
7
Prevalence of different comorbidities in COPD patients by gender and GOLD stage.慢性阻塞性肺疾病(COPD)患者中不同合并症按性别和全球慢性阻塞性肺疾病倡议(GOLD)分级的患病率
Multidiscip Respir Med. 2015 Aug 5;10(1):24. doi: 10.1186/s40248-015-0023-2. eCollection 2015.
8
Cognitive dysfunction in severe chronic obstructive pulmonary disease (COPD) with or without Long-Term Oxygen Therapy (LTOT).伴有或不伴有长期氧疗(LTOT)的重度慢性阻塞性肺疾病(COPD)中的认知功能障碍。
Multidiscip Respir Med. 2015 Apr 19;10(1):17. doi: 10.1186/s40248-015-0013-4. eCollection 2015.
9
Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru.秘鲁四个地理环境不同的资源有限地区慢性阻塞性肺疾病的患病率及危险因素差异
Respir Res. 2015 Mar 18;16(1):40. doi: 10.1186/s12931-015-0198-2.
10
Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.通过胶囊型吸入器和多剂量吸入器以干粉形式联合递送的沙美特罗和丙酸氟替卡松50/100μg的药代动力学比较。
Clin Drug Investig. 2015 May;35(5):319-26. doi: 10.1007/s40261-015-0282-x.
Int J Environ Res Public Health. 2006 Sep;3(3):217-27. doi: 10.3390/ijerph2006030026.
4
Treatment outcome of asthma after one year follow-up in health centres of several developing countries.
Int J Tuberc Lung Dis. 2006 Aug;10(8):911-6.
5
Dissemination and implementation of guidelines for the treatment of asthma.哮喘治疗指南的传播与实施
Int J Tuberc Lung Dis. 2006 Jul;10(7):710-6.
6
Asthma drug facility: from concept to reality.
Int J Tuberc Lung Dis. 2006 Jul;10(7):709.
7
The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews.吸入性糖皮质激素用于治疗哮喘时的剂量-反应特征:Cochrane系统评价概述
Respir Med. 2006 Aug;100(8):1297-306. doi: 10.1016/j.rmed.2006.04.015. Epub 2006 Jun 23.
8
Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes.吸入性糖皮质激素治疗慢性阻塞性肺疾病患者的疗效与安全性:健康结局的系统评价与荟萃分析
Ann Fam Med. 2006 May-Jun;4(3):253-62. doi: 10.1370/afm.517.
9
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.《2001年全球和区域疾病负担及风险因素:对人群健康数据的系统分析》
Lancet. 2006 May 27;367(9524):1747-57. doi: 10.1016/S0140-6736(06)68770-9.
10
Management of chronic asthma in adults in diverse regions of the world.世界不同地区成人慢性哮喘的管理
Int J Tuberc Lung Dis. 2006 May;10(5):474-83.